Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer
Pharmaceutics · 06.05.2026 · 18 (5) · 574
DOI: 10.3390/pharmaceutics18050574 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.05.2026. Verfasst von Angel Phillip und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the National Institutes of Health, Cancer Prevention and Research Institute of Texas, CPRIT.
Abstract (Originalsprache)
Background
Accurate intraoperative identification of ovarian cancer is challenging, as standard techniques such as visual inspection, palpation, and histopathology often fail to detect microscopic disease. Residual tumor contributes to poor cytoreductive outcomes, high recurrence rates, and chemoresistance. Near-infrared (NIR) imaging using tumor-specific biomarkers has emerged as a promising approach to enhance intraoperative visualization and improve tumor margin delineation.
Methods
A focused literature review was conducted using PubMed to identify preclinical and clinical studies evaluating NIR image-guided strategies in ovarian cancer. Studies involving tumor-targeted probes against folate receptor alpha, α3-integrin, mesothelin, and CA125 were included, with emphasis on probe design, delivery, imaging performance, safety, and clinical relevance.
Results
Targeted NIR probes consistently demonstrated improved tumor-to-background contrast, higher lesion detection sensitivity, and enhanced intraoperative guidance compared to conventional imaging. Preclinical and early clinical data indicate favorable safety profiles and minimal off-target toxicity. Evidence suggests that NIR-guided surgery may reduce residual disease burden and potentially improve recurrence-free survival.
Conclusions
Tumor-specific NIR imaging represents a promising pharmaceutics-based strategy for improving surgical outcomes in ovarian cancer. Despite encouraging results, challenges such as biomarker heterogeneity, limited fluorophore availability, and cost must be addressed. Further large-scale, randomized trials are required to validate efficacy and integrate these approaches into clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.
- Division of Cancer and Immunology, Department of Medicine and Oncology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
ORCID-Profile: Annu Karithara, Murali M Yallapu
Förderung
- Foundation for the National Institutes of Health
- Cancer Prevention and Research Institute of Texas
- CPRIT
Zitieren
APA
Phillip, A., Karithara, A., Chauhan, S. C., & Yallapu, M. M. (2026). Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer. Pharmaceutics, 18(5), 574. https://doi.org/10.3390/pharmaceutics18050574
Vancouver
Phillip A, Karithara A, Chauhan SC, Yallapu MM. Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer. Pharmaceutics. 2026;18(5):574. doi:10.3390/pharmaceutics18050574
BibTeX
@article{Phillip2026,
author = {Phillip, Angel and Karithara, Annu and Chauhan, Subhash C and Yallapu, Murali M},
title = {Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {574},
doi = {10.3390/pharmaceutics18050574}
}
EUVIMED